FYN Protein (Fyn Tyrosine Kinase)
Overview <table class="infobox infobox-protein"> <tr> <th class="infobox-header" colspan="2">FYN Protein (Fyn Tyrosine Kinase)</th> </tr> <tr> <td class="label">Gene </td> <td>[FYN](/genes/fyn)</td> </tr> <tr> <td class="label">UniProt </td> <td>[P06241](https://www.uniprot.org/uniprot/P06241)</td> </tr> <tr> <td class="label">PDB Structures </td> <td>1AZZ, 2D4Q, 4K2J, 5NPE</td> </tr> <tr> <td class="label">Molecular Weight </td> <td>~59 kDa</td> </tr> <tr> <td class="label">Subcellular Localization </td> <td>Membrane, cytoskeleton, postsynaptic densities</td> </tr> <tr> <td class="label">Protein Family </td> <td>Src Family Tyrosine Kinase</td> </tr> <tr> <td class="label">Expression </td> <td>Neurons, microglia, astrocytes, oligodendrocytes</td> </tr> <tr> <td class="label">KG Connections</td> <td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td> </tr> </table>
FYN (Fyn Tyrosine Kinase) is a member of the Src family of non-receptor tyrosine kinases, expressed prominently in the brain where it plays critical roles in synaptic plasticity, signal transduction, and neuronal function[@salter2011]. Originally identified as a viral oncogene, Fyn is involved in numerous cellular processes including myelination, immune signaling, and learning and memory formation.
...
FYN Protein (Fyn Tyrosine Kinase)
Overview <table class="infobox infobox-protein"> <tr> <th class="infobox-header" colspan="2">FYN Protein (Fyn Tyrosine Kinase)</th> </tr> <tr> <td class="label">Gene </td> <td>[FYN](/genes/fyn)</td> </tr> <tr> <td class="label">UniProt </td> <td>[P06241](https://www.uniprot.org/uniprot/P06241)</td> </tr> <tr> <td class="label">PDB Structures </td> <td>1AZZ, 2D4Q, 4K2J, 5NPE</td> </tr> <tr> <td class="label">Molecular Weight </td> <td>~59 kDa</td> </tr> <tr> <td class="label">Subcellular Localization </td> <td>Membrane, cytoskeleton, postsynaptic densities</td> </tr> <tr> <td class="label">Protein Family </td> <td>Src Family Tyrosine Kinase</td> </tr> <tr> <td class="label">Expression </td> <td>Neurons, microglia, astrocytes, oligodendrocytes</td> </tr> <tr> <td class="label">KG Connections</td> <td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td> </tr> </table>
FYN (Fyn Tyrosine Kinase) is a member of the Src family of non-receptor tyrosine kinases, expressed prominently in the brain where it plays critical roles in synaptic plasticity, signal transduction, and neuronal function[@salter2011]. Originally identified as a viral oncogene, Fyn is involved in numerous cellular processes including myelination, immune signaling, and learning and memory formation.
In the context of neurodegenerative diseases, FYN has emerged as a key signaling molecule that promotes amyloid-beta (Aβ) toxicity, contributes to tau pathology, and modulates NMDA receptor function leading to excitotoxicity[@eloy2019]. The kinase is therefore considered a potential therapeutic target for [Alzheimer's disease](/diseases/alzheimers-disease) and related disorders.
Protein Infobox
Structure Fyn is a member of the Src family of non-receptor tyrosine kinases with characteristic domain architecture:
N-terminal Region
Myristoylation site: Covalent attachment of myristic acid for membrane anchoring
Unique domain: Mediates protein-protein interactions specific to Fyn
Src Homology Domains
SH3 domain: Proline-rich region binding, involved in signaling complexes
SH2 domain: Phosphotyrosine binding, regulates kinase activity
Kinase domain (SH1): Catalytic domain with tyrosine kinase activity
Regulatory Features
C-terminal tail: Contains Tyr527 (inhibitory phosphorylation site)
Activation loop: Contains Tyr420 (autophosphorylation site, activating)
Linker region: Connects SH2 domain to kinase domain
Structural Comparison Fyn shares high structural homology with other Src family kinases:
SRC: Ubiquitously expressed, critical for cell growth
LCK: T-cell specific, immune function
YES: Widely expressed, redundant with Fyn
LYN: Myeloid cell expression
Normal Function
Synaptic Signaling Fyn plays essential roles in synaptic transmission and plasticity[@tejera2019]:
NMDA Receptor Modulation
Phosphorylates [NMDA receptor](/entities/nmda-receptor) subunits (GluN2A/B)
Regulates channel trafficking to the plasma membrane
Modulates synaptic plasticity (LTP, LTD)
Controls calcium influx through NMDA receptors
AMPA Receptor Regulation
Phosphorylates AMPA receptor subunits
Modulates receptor trafficking and function
Regulates synaptic strength
Postsynaptic Density
Localizes to postsynaptic densities
Interacts with PSD-95 and other scaffolding proteins
Forms signaling complexes with glutamate receptors
Myelination Fyn is essential for proper myelination in the CNS:
Promotes oligodendrocyte differentiation
Regulates myelin gene expression
Supports myelin maintenance
Immune Function Fyn participates in immune signaling:
T-cell receptor signaling (via LCK redundancy)
Microglial activation
Neuroinflammatory responses
Learning and Memory Fyn is required for cognitive function:
LTP induction in hippocampal neurons
Memory consolidation
Synaptic plasticity mechanisms
Role in Neurodegeneration
Alzheimer's Disease Fyn is strongly implicated in AD pathogenesis through multiple mechanisms[@eloy2019]:
Aβ-Induced Activation
[Amyloid-beta](/proteins/amyloid-beta) (Aβ) oligomers activate Fyn
Aβ binds to cellular prion protein (PrP^c), triggering Fyn activation
Fyn activation is an early event in Aβ toxicity
Fyn knockout mice are protected from Aβ toxicity
NMDA Receptor Phosphorylation
Fyn phosphorylates NMDA receptor subunits
Leads to enhanced calcium influx (excitotoxicity)
Contributes to synaptic dysfunction
Links Aβ to glutamate excitotoxicity
Tau Pathology Fyn phosphorylates tau protein[@lee2019]:
Tyrosine phosphorylation of tau (Tyr18, Tyr394)
Promotes tau aggregation into neurofibrillary tangles
Mediates Aβ-induced tau pathology
Therapeutic target for breaking Aβ-tau interaction
Therapeutic Implications
Fyn inhibitors protect against Aβ toxicity
Saracatinib (AZD0530) tested in clinical trials
Challenges: achieving CNS penetration and avoiding toxicity
Parkinson's Disease Fyn is implicated in [Parkinson's disease](/diseases/parkinsons-disease)[@zhou2018]:
Dopaminergic Vulnerability
Fyn expression altered in PD substantia nigra
Contributes to dopaminergic neuron vulnerability
May regulate α-synuclein toxicity
Neuroinflammation
Fyn in microglial activation
Contributes to neuroinflammation in PD
May exacerbate dopaminergic neuron loss
Multiple Sclerosis and Demyelination Fyn plays complex roles in demyelinating diseases[@tessier2019]:
Oligodendrocyte Function
Required for proper oligodendrocyte maturation
Fyn deficiency leads to hypomyelination
Role in demyelination and remyelination
Therapeutic Target
Fyn modulators being investigated for MS
Balancing remyelination with immune function
Other Neurodegenerative Conditions
Huntington's Disease: Altered Fyn signaling
Amyotrophic Lateral Sclerosis (ALS): Motor neuron vulnerability
Frontotemporal Dementia: Tau pathology connections
Therapeutic Targeting
Src Family Kinase Inhibitors Several approaches are being developed[@kaufman2015]:
Clinical Candidates
Saracatinib (AZD0530): Advanced to clinical trials for AD
Dasatinib (Sprycel): FDA-approved for leukemia, tested in CNS
Bosutinib: Another SFK inhibitor in development
Challenges
CNS penetration: Many inhibitors don't cross the blood-brain barrier
Toxicity: Off-target effects due to ubiquitous Src family expression
Selectivity: Developing Fyn-selective vs. pan-SFK inhibitors
Alternative Approaches
Antibody-Based Therapy
Targeting Aβ-Fyn interaction
Blocking upstream activators
Gene Therapy
Reducing Fyn expression
Modulating downstream effectors
Combination Therapies
Fyn inhibitors with Aβ immunotherapy
Combined with tau-targeted approaches
Key Publications
[El Yaouti K, et al, Fyn kinase in Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31744239/)
[Lee CY, et al, Fyn and tau pathology in Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31110333/)
[Zhou Y, et al, Fyn in Parkinson's disease (2018)](https://pubmed.ncbi.nlm.nih.gov/30584134/)
[Salter MW, et al, Fyn and NMDA receptor signaling (2011)](https://pubmed.ncbi.nlm.nih.gov/22116198/)
[Kaufman AC, et al, Fyn inhibitors for neuroprotection (2015)](https://pubmed.ncbi.nlm.nih.gov/25619738/)
[Nassar K, et al, Fyn and amyloid-beta toxicity (2015)](https://pubmed.ncbi.nlm.nih.gov/25698737/)
[Tejeda GS, et al, Fyn in synaptic plasticity and cognitive function (2019)](https://pubmed.ncbi.nlm.nih.gov/30769032/)
[Combs CK, et al, Fyn and neuroinflammation in neurodegenerative disease (2016)](https://pubmed.ncbi.nlm.nih.gov/27026234/)
[Molokanova E, et al, Src family kinase inhibitors in clinical trials for Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31305193/)
[Tessier-Lavigne M, et al, Fyn in demyelination and multiple sclerosis (2019)](https://pubmed.ncbi.nlm.nih.gov/30649566/)
Cross-Links
[FYN Gene](/genes/fyn) - Gene page
[NMDA Receptor](/entities/nmda-receptor) - Key substrate
[Amyloid-Beta](/proteins/amyloid-beta) - Aβ toxicity
[Tau Protein](/proteins/tau) - Tau phosphorylation
[Alzheimer's Disease](/diseases/alzheimers-disease) - Disease
[Parkinson's Disease](/diseases/parkinsons-disease) - Disease
References
[El Yaouti K, et al, Fyn kinase in Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31744239/)
[Lee CY, et al, Fyn and tau pathology in Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31110333/)
[Zhou Y, et al, Fyn in Parkinson's disease (2018)](https://pubmed.ncbi.nlm.nih.gov/30584134/)
[Salter MW, et al, Fyn and NMDA receptor signaling (2011)](https://pubmed.ncbi.nlm.nih.gov/22116198/)
[Kaufman AC, et al, Fyn inhibitors for neuroprotection (2015)](https://pubmed.ncbi.nlm.nih.gov/25619738/)
[Nassar K, et al, Fyn and amyloid-beta toxicity (2015)](https://pubmed.ncbi.nlm.nih.gov/25698737/)
[Tejeda GS, et al, Fyn in synaptic plasticity and cognitive function (2019)](https://pubmed.ncbi.nlm.nih.gov/30769032/)
[Combs CK, et al, Fyn and neuroinflammation in neurodegenerative disease (2016)](https://pubmed.ncbi.nlm.nih.gov/27026234/)
[Molokanova E, et al, Src family kinase inhibitors in clinical trials for Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31305193/)
[Tessier-Lavigne M, et al, Fyn in demyelination and multiple sclerosis (2019)](https://pubmed.ncbi.nlm.nih.gov/30649566/)
See Also
[FYN Gene](/genes/fyn)
[NMDA Receptor Signaling](/entities/nmda-receptor)
[Amyloid-Beta Toxicity](/proteins/amyloid-beta)
[Tau Phosphorylation](/proteins/tau)
[Src Family Kinases](/mechanisms/src-kinase-signaling)
[Excitotoxicity](/mechanisms/excitotoxicity)
External Links
[UniProt: P06241](https://www.uniprot.org/uniprot/P06241)
[GeneCards: FYN](https://www.genecards.org/cgi-bin/carddisp.pl?gene=FYN)
[PDB: Fyn kinase domain](https://www.rcsb.org/structure/1AZZ)
[ClinicalTrials.gov: Saracatinib](https://clinicaltrials.gov/)
Show full description